

Sang Joon Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2345316/publications.pdf>

Version: 2024-02-01

16
papers

1,457
citations

1039880

9
h-index

940416

16
g-index

16
all docs

16
docs citations

16
times ranked

1380
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 1385-1395.	0.9	10
2	Current Issues in Analytical Similarity Assessment. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 203-209.	0.6	2
3	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	1.6	18
4	Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. <i>Clinical and Translational Science</i> , 2021, 14, 1280-1291.	1.5	11
5	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4323-4333.	1.1	7
6	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 631-640.	1.1	11
7	Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness. <i>Advances in Therapy</i> , 2021, 38, 4366-4387.	1.3	10
8	Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection. <i>Clinical Therapeutics</i> , 2021, 43, 1706-1727.	1.1	39
9	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361.	2.5	6
10	Some thoughts on the QR method for analytical similarity evaluation. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 521-536.	0.4	2
11	Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. <i>BioDrugs</i> , 2020, 34, 513-528.	2.2	10
12	A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 505-514.	1.1	32
13	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology</i> , 2017, 18, 917-928.	5.1	93
14	Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 35-44.	1.4	100
15	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1613-1620.	0.5	575
16	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1605-1612.	0.5	531